CureVac and Sanofi Pasteur to develop an mRNA-based prophylactic vaccine

Manufacturing Chemist Group

首页> 外文期刊>Manufacturing Chemist: Pharmaceutical Development, Formulation, Processing and Outsourcing >CureVac and Sanofi Pasteur to develop an mRNA-based prophylactic vaccine

【24h】

CureVac and Sanofi Pasteur to develop an mRNA-based prophylactic vaccine

机译：CureVac和赛诺菲巴斯德开发基于mRNA的预防性疫苗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

CureVac, a German clinical-stage biopharmaceutical company, and Sanofi Pasteur, the vaccines division of Sanofi, are to develop and commercialise a new mRNA-based vaccine. Sanofi Pasteur has exercised its option for exclusive and non-exclusive rights to develop and commercialise the vaccine against an undisclosed pathogen, in a deal that will see Sanofi Pasteur pay CureVac ?150.5m.

机译：德国临床阶段生物制药公司CureVac和赛诺菲疫苗部门赛诺菲巴斯德（Sanofi Pasteur）将开发和商业化一种基于mRNA的新型疫苗。赛诺菲巴斯德已行使其专有权和非独占权，可以开发针对未公开病原体的疫苗并将其商业化，这笔交易将使赛诺菲巴斯德向CureVac支付1.505亿欧元。

著录项

来源
《Manufacturing Chemist: Pharmaceutical Development, Formulation, Processing and Outsourcing》 |2014年第8期|共1页
作者
Manufacturing Chemist Group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类化学工业;
关键词

相似文献

外文文献
中文文献
专利

1. CureVac and Sanofi Pasteur to develop an mRNA-based prophylactic vaccine [J] . Manufacturing Chemist Group Manufacturing Chemist: Pharmaceutical Development, Formulation, Processing and Outsourcing . 2014,第7a8期

机译：CureVac和赛诺菲巴斯德开发基于mRNA的预防性疫苗
2. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD (TM) vaccine? [J] . Whitehead Stephen S. Expert review of vaccines . 2016,第4期

机译：开发TV003 / TV005单剂量高免疫原性减毒活登革热疫苗;是什么使该疫苗与赛诺菲-巴斯德CYD（TM）疫苗不同？
3. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. (Special Issue: The development of dengue vaccines.) [J] . Guy B., Barrere B., Malinowski C., Vaccine . 2011,第42期

机译：从研究到第三阶段：赛诺菲巴斯德四价登革热疫苗的临床前，工业和临床开发。（特刊：登革热疫苗的开发。）
4. RNActive®-AN mRNA-BASED VACCINE TECHNOLOGY FOR NEXT GENERATION PROPHYLACTIC VACCINES [C] . Edith Jasny Conference on vaccine technology VI . 2018

机译：基于RNActive®-ANmRNA的疫苗技术，可用于下一代新一代预防性疫苗
5. Plasmid DNA as a Platform for the Development of Prophylactic and Therapeutic Vaccines Against Clostridium difficile in Aging Models of Disease [D] . Ramamurthi, Arjun 2017

机译：质粒DNA作为在疾病老龄化模型中开发针对艰难梭菌的预防和治疗疫苗的平台
6. Development of TV003/TV005 a single dose highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? [O] . Stephen S. Whitehead -1

机译：开发TV003 / TV005单剂量高免疫原性减毒活登革热疫苗；是什么使该疫苗与赛诺菲-巴斯德CYD™疫苗不同？
7. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment [O] . Ferguson, NM, Rodriguez-Barraquer, I, Dorigatti, I, 2016

机译：sanofi-pasteur登革热疫苗的益处和风险：建模最佳部署
8. Anthrax Vaccines: Pasteur to the Present [R] . Scorpio, A. , Blank, T. E. , Day, W. A. , 2006

机译：炭疽疫苗：巴斯德到现在

CureVac and Sanofi Pasteur to develop an mRNA-based prophylactic vaccine

摘要

著录项

相似文献

相关主题

期刊订阅